Mrs Kimberly Anne Enriquez, OTR/L | |
38416 N 29th Ave, Desert Hills, AZ 85086-9125 | |
(623) 326-4302 | |
Not Available |
Full Name | Mrs Kimberly Anne Enriquez |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 38416 N 29th Ave, Desert Hills, Arizona |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740682509 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | AZ1380 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Kimberly Anne Enriquez, OTR/L 38416 N 29th Ave, Desert Hills, AZ 85086-9125 Ph: (623) 326-4302 | Mrs Kimberly Anne Enriquez, OTR/L 38416 N 29th Ave, Desert Hills, AZ 85086-9125 Ph: (623) 326-4302 |
News Archive
A study of long-term, active duty military personnel who used Department of Veterans Affairs' health services showed that childhood maltreatment and other high magnitude stressors, such as being in a serious accident or a natural disaster, were more strongly associated with participants' current psychiatric symptoms than were their military sexual experiences, such as sexual harassment.
ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.
In their study published in the American Journal of Respiratory and Critical Care Medicine they looked at nearly 1,500 children from birth to ages eight to 14. Parents provided information on breastfeeding history when their children were 12 months old, and the children had a series of tests to assess lung function between the ages of 8 and 14.
Phase 1 trial results published in The Lancet Infectious Diseases found a new subunit vaccine —an MF59-adjuvanted subunit vaccine using recombinant spike glycoprotein stabilized in a prefusion conformation by a novel molecular clamp — targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was safe and effective in producing an antigen-specific response in healthy adults.
› Verified 5 days ago